Biological dosimeters and neutron capture therapy systems incorporating them

By measuring the degree of protein degradation in a radiation field and calculating the radiation dose using a standard curve, the problems of complex operation and inaccurate measurement in existing technologies are solved, and simplified radiation dose measurement and dose assessment in neutron capture therapy systems are realized.

CN117130035BActive Publication Date: 2026-11-10NEUBORON MEDTECH LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311087583.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2017-08-18
Publication Date
2026-11-10
Estimated Expiration
2037-08-18

AI Technical Summary

Technical Problem

Existing biological dosimeters have complicated operating procedures, making it difficult to accurately measure radiation dose, and there is a lack of effective means of radiation dose assessment in neutron capture therapy.

Method used

By measuring the degree of protein degradation in a radiation field, a standard curve is plotted using methods such as SDS-gel electrophoresis, and the change in protein molecular weight is calculated to quantify the radiation dose. This method, combined with adjustments based on protein concentration and radiation time, is suitable for dose measurement in different radiation fields.

Benefits of technology

A simplified, sensitive, and accurate method for measuring radiation dose is provided, applicable to low to high dose ranges, and suitable for dose assessment in environmental radiation detection and neutron capture therapy systems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117130035B_ABST
    Figure CN117130035B_ABST
Patent Text Reader

Abstract

A biodosimeter, its method of use, and a neutron capture therapy system including the biodosimeter are disclosed. The biodosimeter measures the dose received by a protein in a radiation field based on the degree of protein degradation in the radiation field. The biodosimeter is simple to operate, involves few steps, has low error, and can measure radiation doses in multiple radiation fields, even mixed radiation fields. Its application in a neutron capture therapy system can not only assess radiation contamination in the irradiation room but also evaluate neutron doses.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates, on one hand, to the field of radiation dose measurement, and more particularly to a biological dosimeter and its method of use; on the other hand, this invention relates to the field of radiation irradiation, and more particularly to a neutron capture therapy system with a biological dosimeter. Background Technology

[0002] With the development of science and technology, nuclear technology has been widely used in various fields such as medicine, industry, and agriculture. While benefiting mankind, nuclear technology also poses certain risks of nuclear leakage, endangering public health and polluting the surrounding environment. Therefore, it is necessary to determine the radiation dose in the environment to further assess the impact of radiation dose on humans or the environment, and to take certain control measures for radiation dose in the environment.

[0003] Neutron capture therapy, as an effective treatment for cancer, has seen increasing application in recent years, with boron neutron capture therapy being the most common. Neutrons supplied for boron neutron capture therapy can be provided by nuclear reactors or accelerators, carrying neutrons containing... 10 Compound B accumulates at the lesion site, containing neutrons and... 10 Compound B undergoes the following reaction:

[0004]

[0005] The energy generated by this reaction destroys the lesion to achieve the therapeutic goal. During BNCT (Brain-Neuro-Treating Therapy), if the neutron dose is too low, the boron-containing compounds in the lesion will not react sufficiently with the neutrons, and the patient will need to receive radiation for a longer period. Conversely, if the neutron dose is too high, it is often accompanied by gamma ray or other radiation source contamination, posing a threat to the safety of patients and medical staff. Therefore, it is necessary to pre-assess the radiation dose received by the patient before neutron irradiation to complete the treatment with minimal radiation damage.

[0006] Currently known biological dosimeters mainly utilize the effects of radiation on RNA transcription or protein expression to measure the dose received by biomolecules. However, these techniques typically require a series of complex steps, such as cell culture, protein separation, and calculations, making the operation process cumbersome and prone to errors. Summary of the Invention

[0007] To provide a biological dosimeter that simplifies procedures, is easy to operate, and can accurately measure radiation dose, the present invention provides a biological dosimeter that measures the dose received by a protein in a radiation field based on the degree of protein degradation in the radiation field.

[0008] The degree of protein degradation can be measured by methods well known to those skilled in the art, such as viscometry, gel filtration chromatography, gel permeation chromatography, gel electrophoresis, light scattering, electrospray ionization mass spectrometry (ESI-MS), matrix-assisted laser desorption / ionization mass spectrometry (MALDI-MS), or other methods capable of determining the molecular weight of proteins, to determine the molecular weight of proteins before and after irradiation.

[0009] Preferably, in the biological dosimeter, the molecular weight of the protein before and after radiation irradiation is determined by SDS-gel electrophoresis, and the degree of protein degradation after radiation irradiation is calculated.

[0010] In this embodiment of the invention, the ratio of the molecular weight of the protein after irradiation to the molecular weight of the protein before irradiation is used to quantify the degree of protein degradation.

[0011] Preferably, in the biological dosimeter, the radiation field includes a gamma radiation field, a proton radiation field, a heavy ion radiation field, or a mixed radiation field of neutrons and gamma.

[0012] The biodosimeter measures radiation dose through the following steps.

[0013] 1) Steps for plotting a standard curve: Plot a standard curve of radiation dose and protein degradation degree. Then, substitute the degree of protein degradation in the radiation field to be tested into the function corresponding to the standard curve to obtain the radiation dose received by the protein in the radiation field to be tested. It should be noted that the radiation dose calculated by the standard curve is the dose of the protein in the radiation field used to plot the standard curve. When the radiation field to be tested is different from the radiation field used to plot the standard curve, the dose value calculated by the standard curve needs to be converted into the dose of the actual radiation field to be tested. Specifically, the conversion coefficient of radiation dose between the two different types of radiation fields needs to be calculated experimentally, and then the calculated radiation dose is converted into the dose of the actual radiation field to be used according to the coefficient.

[0014] For example, multiple groups of proteins can be irradiated with different doses of gamma rays in a gamma radiation field. The molecular weight and radiation dose received by the proteins before and after irradiation can be measured and calculated. When plotting the standard curve, the radiation dose received by the proteins in the gamma radiation field is measured using radiochromic film (e.g., radiochromic film or alanine), and the standard curve is plotted and fitted.

[0015] 2) Steps for measuring the dose of the radiation field to be tested: Prepare a protein solution with the same concentration as in the above steps, and irradiate it in an unknown intensity (to be tested) gamma radiation field, proton radiation field, heavy ion radiation field, or a mixed radiation field of neutrons and gamma. After irradiation, measure the molecular weight of the protein before and after irradiation, calculate its degree of degradation, and substitute the value representing the degree of protein degradation into the standard curve mentioned above to calculate the radiation dose received by the protein in the radiation field to be tested. This dose is expressed in gamma rays. When the radiation field to be tested is a gamma radiation field, the radiation dose can be considered as the actual dose received by the protein in the gamma radiation field. When the radiation field to be tested is a proton radiation field, it is necessary to calculate the intensity conversion coefficient between gamma rays and proton radiation through experiments, and further calculate the actual dose received by the protein in the proton radiation field during the irradiation time. Similarly, the standard curve plotted using the protein in the gamma radiation field can also be used to measure the radiation dose of other types of radiation fields.

[0016] More preferably, in the biological dosimeter, when the dose of the radiation field to be measured is less than 1000 Gy, the protein is selected as a protein sensitive to radiation.

[0017] Radiation-sensitive proteins are those whose molecular weight after irradiation is less than 0.8 when exposed to a radiation dose of 1000 Gy and whose concentration is less than 1 g / L. These radiation-sensitive proteins include, but are not limited to, bovine serum albumin (BSA), ovalbumin, catalase, and transferrin.

[0018] It should be noted that the radiation dose that the biological dosimeter provided in this embodiment of the invention can measure is not limited to less than 1000 Gy. When the radiation dose to be measured is higher than 1000 Gy, proteins with different sensitivities to radiation can be selected according to the radiation intensity of the specific radiation field to be measured. For example, when it is necessary to measure a radiation field with a radiation dose of 1000 Gy to 8000 Gy, the degree of degradation of casein in the radiation field can be used to measure the specific radiation dose it receives. Casein has higher stability in the radiation field than bovine serum albumin.

[0019] Preferably, when the radiation dose to be measured is higher than 1000 Gy, casein is selected as a biological dosimeter to measure the radiation dose in the radiation field.

[0020] Preferably, in the biological dosimeter, the protein concentration is a bovine serum albumin solution with a concentration of 0.2 g / L to 0.6 g / L.

[0021] The embodiments of the present invention have shown that low concentrations of proteins have good sensitivity in a radiation field, and the degree of protein degradation has a good linear relationship with the intensity of the radiation field.

[0022] More preferably, in the biological dosimeter, the 0.2 g / L to 0.6 g / L bovine serum albumin solution is used to measure a radiation dose of 100 Gy to 500 Gy.

[0023] The biodosimeter provided in this invention, composed of low-concentration (e.g., less than 1 g / L) protein, exhibits high sensitivity and accuracy when measuring low-dose radiation fields. When measuring high-intensity radiation fields, a protein solution with a concentration higher than 1 g / L can be used to plot a standard curve; alternatively, when using a low-concentration protein as the biodosimeter, the low-concentration protein receives short-term irradiation in a high-intensity radiation field. As is well known to those skilled in the art, in a radiation field of a given intensity, the longer the irradiation time, the greater the radiation dose received by the protein; conversely, the shorter the irradiation time, the less radiation dose received by the protein. Therefore, by changing the irradiation time of the protein in the radiation field, the radiation dose received by the protein can be reduced, and a standard curve plotted using a lower concentration of protein can be used to improve the dose measurement sensitivity.

[0024] Another aspect of the present invention provides a method of using the biodosimeter, wherein the biodosimeter measures radiation dose through the following steps:

[0025] The steps for plotting a standard curve are as follows: prepare multiple groups of protein solutions, place the protein solutions in a radiation field and expose them to different doses of radiation, terminate the radiation, measure the radiation dose received by each group of protein solutions and analyze the degree of protein degradation after irradiation, and plot and fit a standard curve of radiation dose and degree of protein degradation.

[0026] The steps for measuring the dose of the radiation field to be tested are as follows: Prepare a protein solution of the same concentration as in the above steps, place the protein solution in the radiation environment to be tested to receive radiation, terminate the radiation and measure the degree of protein degradation after radiation, and substitute the value that can reflect the degree of protein degradation into the above standard curve to calculate the radiation dose received by the protein during the time of radiation exposure.

[0027] Preferably, in the method of use, when the radiation dose calculated by measuring the dose of the radiation field to be measured is not within the range of the radiation dose used when plotting the standard curve, the accuracy of measuring the dose of the radiation field to be measured can be further improved by adjusting the irradiation time of the protein solution in the step of measuring the dose of the radiation field to be measured so that the radiation dose received by the protein solution is within the range of the radiation dose used when plotting the standard curve.

[0028] More preferably, in the method of use, the protein solution is a bovine serum albumin solution with a concentration of 0.2 g / L to 0.6 g / L.

[0029] A third aspect of this invention provides a neutron capture therapy system for measuring neutron intensity during neutron capture therapy. The system includes a neutron source, a beam shaper, a collimator, and any of the biodosimeters described above. The neutron source generates a neutron beam. The beam shaper is located behind the neutron source and modulates fast neutrons in the broad-spectrum neutron beam into hyperthermic neutrons. The collimator is located behind the beam shaper and focuses the hyperthermic neutrons, directing the beam to a specific spatial location for precise treatment. The biodosimeter measures the radiation dose at its location behind the collimator. The hyperthermic neutron energy range is between 0.5 eV and 40 keV, and the fast neutron energy range is greater than 40 keV.

[0030] Preferably, in the neutron capture therapy system, the biodosimeter is located at a specific spatial position irradiated by the hyperthermic neutron beam, and can measure the radiation dose to be received by the patient before neutron capture therapy, and can also monitor the radiation dose in the irradiation room during neutron capture therapy.

[0031] More preferably, in the neutron capture therapy system, the neutron source is an accelerator neutron source or a reactor neutron source.

[0032] More preferably, in the neutron capture therapy system, the beam shaper includes a reflector and a retarder, wherein the reflector surrounds the retarder and is used to reflect neutrons diffusing out of the beam shaper back into the retarder, and the retarder is used to slow fast neutrons into hyperthermal neutrons.

[0033] The biodosimeter provided in this invention uses the degree of protein degradation in a radiation field to measure the radiation dose of an unknown intensity radiation field, so as to further evaluate or regulate the intensity of the radiation field. The biodosimeter provided in this invention has high sensitivity and is simple to operate. In addition to detecting low-dose radiation leakage in the environment, it can also be applied to the prediction and regulation of neutron dose in neutron capture therapy systems. Attached Figure Description

[0034] Figure 1 This is the standard curve of a 0.3 g / L bovine serum albumin solution in a gamma radiation field;

[0035] Figure 2 This is the standard curve of a 0.2 g / L bovine serum albumin solution in a gamma radiation field;

[0036] Figure 3 This is the standard curve of a 0.5 g / L bovine serum albumin solution in a gamma radiation field;

[0037] Figure 4 This is the standard curve of a 0.6 g / L bovine serum albumin solution in a gamma radiation field;

[0038] Figure 5 It is a neutron capture therapy system containing a biological dosimeter. Detailed Implementation

[0039] The present invention will now be described in further detail with reference to the accompanying drawings, so that those skilled in the art can implement it based on the description. It should be understood that the above brief description and the following detailed description are exemplary and for explanation only, and do not limit the subject matter of the present invention in any way.

[0040] It should be understood that terms such as “having,” “comprising,” and “including” as used herein do not exclude the presence or addition of one or more other ingredients or combinations thereof.

[0041] To clearly illustrate the technical solution of this invention, the terms appearing in this invention are defined as follows:

[0042] The degree of protein degradation is the ratio of the protein's molecular weight before and after irradiation.

[0043] The value calculated by substituting the numerical value of the degree of protein degradation in the radiation field to be measured into the standard curve is called the radiation dose;

[0044] When the radiation field to be measured is different from the radiation field used to plot the standard curve, the radiation dose is called the relative dose.

[0045] When the radiation field to be measured and the radiation field used to plot the standard curve belong to the same type of radiation field, the radiation dose is called the actual dose.

[0046] The biodosimeter provided by this invention can measure radiation dose in various radiation fields (including mixed radiation fields) by utilizing the degree of protein degradation in a radiation field. The method of using the biodosimeter includes two steps:

[0047] The steps for plotting a standard curve are as follows: prepare multiple groups of protein solutions, place the protein solutions in a radiation field and irradiate them with different doses of radiation, terminate the radiation, measure the radiation dose received by each group of protein solutions and analyze the degree of protein degradation after irradiation, and plot and fit a standard curve of radiation dose and degree of protein degradation.

[0048] The steps for measuring the dose of the radiation field to be tested are as follows: Prepare a protein solution of the same concentration as in the above steps, place the protein solution in the radiation environment to be tested to receive radiation, terminate the radiation and measure the degree of protein degradation after radiation, and substitute the value that can reflect the degree of protein degradation into the above standard curve to calculate the radiation dose received by the protein during the time of radiation exposure.

[0049] The following examples, in conjunction with accompanying drawings, illustrate the use of a biodosimeter and the plotting of its standard curve: <Example 1> Plotting the Biodosimeter Standard Curve

[0050] The standard curve plotted by the biological dosimeter provided by this invention can be plotted according to the degree of protein degradation in any type of radiation field. In this embodiment, the standard curve is plotted using the degree of degradation of bovine serum albumin in a gamma radiation field to illustrate the method of plotting the standard curve.

[0051] Proteins of different concentrations degrade to different degrees in a radiation field. Protein concentration is a factor that affects the degree of degradation in a radiation field. The following standard curves plotted using the degradation degree of proteins of different concentrations in a gamma radiation field will further illustrate this.

[0052] Plotting the standard curve of a 0.3 g / L bovine serum albumin solution in a gamma radiation field:

[0053] 0.03 g of BSA was dissolved in 100 g of distilled water to prepare a BSA solution with a concentration of 0.3 g / L. The BSA solution was mixed evenly and divided into several equal portions. Six portions of the BSA solution were placed in a gamma radiation field to receive different doses of gamma radiation. The doses received by each portion of the BSA solution in the radiation field were measured using a Gafchromic film and found to be 118 Gy, 258 Gy, 337 Gy, 358 Gy, 370 Gy, and 405 Gy.

[0054] Proteins without radiation exposure and proteins exposed to different doses of radiation were subjected to SDS-gel electrophoresis, and their molecular weights were calculated using Image J. The ratio of the molecular weight of the irradiated protein to that of the unirradiated protein was used to describe the degree of protein degradation under that radiation dose. The results are shown in Table 1.

[0055] Table 1. Degradation of 0.3 g / L bovine serum albumin under different doses of gamma radiation.

[0056]

[0057] Based on the above experimental data, a functional curve relating the degree of protein degradation to the radiation dose received by the protein was fitted, as shown in the attached figure. Figure 1 As shown, from Figure 1 The standard curve fitted to 0.3 g / L bovine serum albumin shows that, within the radiation dose range of 118 Gy to 405 Gy, there is a good linear relationship between the degree of protein degradation and the corresponding radiation dose.

[0058] The degradation rates of bovine serum albumin solutions with concentrations of 0.2 g / L, 0.5 g / L, and 0.6 g / L in a gamma radiation field were calculated using the same methods and procedures, as shown in Tables 2, 3, and 4.

[0059] Table 2. Degradation of 0.2 g / L bovine serum albumin under different doses of gamma radiation.

[0060]

[0061] Table 3. Degradation of 0.5 g / L bovine serum albumin under different doses of gamma radiation.

[0062]

[0063] Table 4. Degradation of 0.6 g / L bovine serum albumin under different doses of gamma radiation.

[0064]

[0065] Table 5. Degradation of 0.1 g / L bovine serum albumin under different doses of gamma radiation.

[0066]

[0067]

[0068] Table 6. Degradation of 1 g / L bovine serum albumin under different doses of gamma radiation.

[0069]

[0070] Based on the experimental data in Tables 2 to 4, plots are shown below. Figures 2-4 The standard curves showing the degradation degree of proteins of different concentrations in a radiation field are shown. It can be seen from the figure that the degradation degree of proteins of different concentrations in a radiation field has a good linear relationship with the radiation dose they receive.

[0071] Tables 5 and 6 show the degradation degree of bovine serum albumin at concentrations of 0.1 g / L and 1 g / L under different doses of gamma radiation. The data in these two tables show that the degradation degree of protein in the radiation field has a linear relationship with the radiation dose received, indicating that protein solutions with concentrations below 0.2 g / L or above 0.6 g / L can also be used as biological dosimeters.

[0072] A standard curve can be used to detect the radiation dose of proteins of the same concentration in an unknown intensity and type of radiation field. The radiation dose calculated by substituting into the standard curve is expressed as the dose of gamma rays. When the unknown type of radiation field is a gamma radiation field, the calculated radiation dose is the same as the actual radiation dose received by the protein in the radiation field to be measured. When the unknown type of radiation field is not a gamma radiation field, the calculated radiation dose is the relative dose of the protein in the unknown radiation field, and further calculations are needed by experimentally calculating the conversion coefficient between the gamma radiation field and the radiation field to be measured.

[0073] <Example 2> Method for measuring the actual radiation dose of a mixed neutron and gamma radiation field using a biodosimeter

[0074] When measuring the intensity of a radiation field using a biodosimeter, a standard curve can be prepared in advance between the degree of protein degradation and the radiation dose based on the type of radiation field to be measured. Alternatively, a standard curve prepared using a non-radiation field to be measured can be used, and the actual radiation dose of the radiation field to be measured can be measured by using the conversion coefficient between the radiation field to be measured and the radiation field used in the standard curve.

[0075] The conversion coefficient between radiation fields needs to be further confirmed through experiments. This embodiment takes the calculation method of the conversion coefficient between gamma radiation field and neutron radiation field as an example to illustrate the calculation method of the conversion coefficient between different radiation fields.

[0076] As in Example 1, a protein solution of a specific concentration was prepared, and the protein solution was placed in a gamma radiation field to receive different doses (Dγ1, Dγ2...Dγ). n Gamma-ray irradiation was applied, and the protein's activity at Dγ1, Dγ2...Dγ was calculated. n Degradation degree under radiation dose X1, X2...X n .

[0077] Prepare protein solutions of the specific concentrations mentioned above and irradiate them in a neutron radiation field. When the degree of protein degradation in the neutron radiation field is the same as the degree of protein degradation in the gamma radiation field (i.e., the degree of protein degradation in the neutron radiation field is X1, X2...X...), the protein degradation is considered to be at the same level. n (Time) Read the neutron doses received by the protein Dn1, Dn2, ... Dn n .

[0078] The ratio of gamma dose to neutron dose for a protein at a specific degree of degradation is defined as the conversion factor between neutrons and gamma rays for that degree of degradation.

[0079] K i =Dγ i / Dn i (where i takes values ​​from 1 to n)

[0080] Plot a curve between the degree of protein degradation and the conversion coefficient corresponding to that degree of degradation, and fit the function to the curve:

[0081] K i =f(Xi)

[0082] When calculating the relative radiation dose of a protein in a neutron radiation field using a standard curve derived from a gamma radiation field, the degree of protein degradation is first substituted into the function K. i =f(Xi) calculates the conversion coefficient at this degree of degradation, and then calculates the actual neutron radiation dose received by the protein in the neutron radiation field based on the conversion coefficient and the relative radiation dose calculated through the standard curve. The actual neutron radiation dose received by the protein in the neutron radiation field is the ratio of the relative radiation dose to the conversion coefficient.

[0083] In this embodiment, the dose received by the protein in the radiation field is measured and calculated using a radiochromic film. Alternatively, it can be measured using other methods known to those skilled in the art that can measure the radiation dose received by the protein in a radiation field.

[0084] When the radiation field to be measured is a mixed neutron and gamma radiation field, and the standard curve is plotted using the degree of protein degradation in the gamma radiation field, the degree of protein degradation X is calculated using a biodosimeter. i The corresponding radiation dose is the relative radiation dose D of the protein in the gamma radiation field. i D i =M j +N j , of which M j It is the gamma dose, N j The equivalent dose of neutron relative to gamma, wherein the gamma dose M j The actual neutron dose received by the protein can be calculated using Monte Carlo methods. This dose is the neutron equivalent dose relative to gamma and the conversion factor (K) at the protein degradation concentration. i The ratio of ). <Example 3> Neutron capture therapy system including a biodosimeter

[0085] The biological dosimeter provided in this invention is used to detect radiation dose. It can be used not only to detect radiation pollution in the environment, but also to predict the intensity or dose of neutron beams in neutron capture therapy systems to guide the treatment process.

[0086] Neutron capture therapy has seen increasing application as an effective cancer treatment in recent years, with boron neutron capture therapy being the most common. Neutrons for boron neutron capture therapy can be supplied by nuclear reactors or accelerators. This invention uses accelerator-based boron neutron capture therapy as an example. The basic components of accelerator-based boron neutron capture therapy typically include an accelerator for accelerating charged particles (such as protons, deuterons, etc.), a target and thermal removal system, and a beam shaper. The accelerated charged particles interact with the metal target to produce neutrons. A suitable nuclear reaction is selected based on the required neutron yield and energy, the available energy and current of the accelerated charged particles, and the physicochemical properties of the metal target. Commonly discussed nuclear reactions include... 7 Li(p,n) 7 Be and 9 Be(p,n) 9 B. Both of these reactions are endothermic. The energy thresholds for the two nuclear reactions are 1.881 MeV and 2.055 MeV, respectively. Since the ideal neutron source for boron neutron capture therapy is hyperthermal neutrons at the keV energy level, theoretically, if protons with energies only slightly higher than the threshold are used to bombard a lithium metal target, relatively low-energy neutrons can be produced, which can be used clinically without much slowing treatment. However, the interaction cross-section between lithium metal (Li) and beryllium metal (Be) targets and protons at the threshold energy is not high. In order to generate a sufficiently large neutron flux, higher-energy protons are usually selected to initiate the nuclear reaction.

[0087] Ideally, a target material should possess characteristics such as high neutron yield, neutron energy distribution close to the hyperthermic neutron energy region (described in detail below), minimal strong penetration radiation, safety, low cost, ease of operation, and high temperature resistance. However, in reality, it is impossible to find a nuclear reaction that meets all these requirements. In the embodiments of this invention, a target material made of lithium metal is used. However, as those skilled in the art will know, the target material can also be made of other metallic materials besides those discussed above.

[0088] The requirements for a thermal removal system vary depending on the nuclear reaction selected, such as 7 Li(p,n) 7 Due to the difference in melting point and thermal conductivity between the metal target material (lithium metal), the requirements for the heat removal system are relatively high. 9 Be(p,n) 9 B is high. In embodiments of the present invention, the following are employed: 7 Li(p,n) 7 Nuclear reactions of Be.

[0089] Regardless of whether the neutron source for boron neutron capture therapy originates from the nuclear reaction between charged particles and the target material in a nuclear reactor or accelerator, the resulting radiation field is a mixed radiation field, meaning the beam contains neutrons and photons ranging from low to high energy. For boron neutron capture therapy of deep tumors, the higher the content of radiation other than hyperthermic neutrons, the greater the proportion of non-selective dose deposition in normal tissues. Therefore, these radiations that cause unnecessary doses should be minimized. In addition to air beam quality factors, to better understand the dose distribution caused by neutrons in the human body, the embodiments of this invention use a human head tissue prosthesis for dose calculation, and the prosthesis beam quality factor is used as a design reference for the neutron beam, which will be described in detail below.

[0090] The International Atomic Energy Agency (IAEA) has issued five recommendations regarding air beam quality factors for neutron sources used in clinical boron neutron capture therapy. These recommendations can be used to compare the advantages and disadvantages of different neutron sources and serve as a reference for selecting neutron generation pathways and designing beam shapers. The five recommendations are as follows:

[0091] Epithermal neutron flux > 1 x 10⁻⁶ 9 n / cm 2 s

[0092] Fast neutron contamination < 2 x 10⁻⁶ -13 Gy-cm 2 / n

[0093] Photon contamination < 2 x 10⁻⁶ -13 Gy-cm 2 / n

[0094] The thermal to epithermal neutron flux ratio is <0.05.

[0095] The epithermal neutron current to flux ratio is greater than 0.7.

[0096] Note: The ultrathermal neutron energy ranges from 0.5 eV to 40 keV, the thermal neutron energy range is less than 0.5 eV, and the fast neutron energy range is greater than 40 keV.

[0097] 1. Superthermal neutron beam flux:

[0098] The duration of clinical treatment is determined by both the neutron beam flux and the concentration of boron-containing drugs in the tumor. If the concentration of boron-containing drugs in the tumor is high enough, the required neutron beam flux can be reduced; conversely, if the concentration of boron-containing drugs in the tumor is low, a high flux of hyperthermal neutrons is needed to deliver a sufficient dose to the tumor. The IAEA requires a hyperthermal neutron beam flux of greater than 102 hyperthermal neutrons per square centimeter per second. 9 At this flux, the neutron beam can roughly control the treatment time to within one hour for current boron-containing drugs. In addition to the advantages of patient positioning and comfort, the short treatment time can also make more effective use of the limited residence time of boron-containing drugs in the tumor.

[0099] 2. Fast neutron pollution:

[0100] Fast neutrons are considered contamination because they cause unnecessary doses to normal tissues. This dose is positively correlated with neutron energy; therefore, the concentration of fast neutrons should be minimized in neutron beam design. Fast neutron contamination is defined as the fast neutron dose per unit hyperthermic neutron flux. The IAEA recommends a fast neutron contamination dose of less than 2 x 10⁻⁶. -13 Gy-cm 2 / n.

[0101] 3. Photon pollution (gamma-ray pollution):

[0102] Gamma rays are strong penetrating radiation that non-selectively deposit dose on all tissues along the beam path. Therefore, reducing gamma ray content is a necessary requirement for neutron beam design. Gamma ray contamination is defined as the gamma ray dose per unit hyperthermic neutron flux. The IAEA recommends a gamma ray contamination level of less than 2 x 10⁻⁶. -13 Gy-cm 2 / n.

[0103] 4. Ratio of thermal neutron to ultrathermal neutron flux:

[0104] Because thermal neutrons decay rapidly and have poor penetrating power, most of their energy is deposited in skin tissue after entering the body. Except for epidermal tumors such as melanoma, which require thermal neutrons as a neutron source for boron neutron capture therapy, the thermal neutron content should be reduced for deep tumors such as brain tumors. The IAEA recommends a thermal neutron to ultrathermal neutron flux ratio of less than 0.05.

[0105] 5. Neutron current to flux ratio:

[0106] The neutron current-to-flux ratio represents the directionality of the beam. A higher ratio indicates better forward neutron beam directionality. A highly forward-oriented neutron beam can reduce the dose to surrounding normal tissues caused by neutron divergence, and also improves the depth of treatment and the flexibility of positioning. The IAEA recommends a neutron current-to-flux ratio greater than 0.7.

[0107] The dose distribution within the tissue is obtained using a prosthesis, and the prosthesis beam quality factors are derived based on the dose-depth curves of normal tissue and tumors. The following three parameters can be used to compare the therapeutic benefits of different neutron beams.

[0108] 1. Effective treatment depth:

[0109] The tumor dose is equal to the depth at which the maximum dose to normal tissue is reached. Beyond this depth, tumor cells receive a lower dose than the maximum dose to normal tissue, thus losing the advantage of boron neutron capture. This parameter represents the penetrating power of the neutron beam; a greater effective treatment depth indicates a deeper tumor that can be treated, measured in centimeters.

[0110] 2. Effective therapeutic depth dose rate:

[0111] The effective treatment depth dose rate is equal to the maximum dose rate to normal tissue. Since the total dose received by normal tissue affects the total dose that can be delivered to the tumor, this parameter affects the treatment time. A higher effective treatment depth dose rate means that the irradiation time required to deliver a certain dose to the tumor is shorter. The unit is cGy / mA-min.

[0112] 3. Effective therapeutic dose ratio:

[0113] The ratio of the average dose received by tumor and normal tissue from the brain surface to the effective treatment depth is called the effective treatment dose ratio; the average dose can be calculated by integrating the dose-depth curve. The higher the effective treatment dose ratio, the better the therapeutic benefit of the neutron beam.

[0114] To provide a basis for comparison in the design of beam shapers, in addition to the five IAEA-recommended airborne beam quality factors and the three parameters mentioned above, the embodiments of this invention also utilize the following parameters for evaluating the performance of neutron beam dosing:

[0115] 1. Irradiation time ≤ 30 min (the proton current used in the accelerator is 10 mA)

[0116] 2. 30.0 RBE-Gy can treat depths ≥7cm

[0117] 3. Maximum tumor dose ≥ 60.0 RBE-Gy

[0118] 4. Maximum dose to normal brain tissue ≤12.5 RBE-Gy

[0119] 5. Maximum skin dose ≤ 11.0 RBE-Gy

[0120] Note: RBE (Relative Biological Effectiveness) is a relative biological effect. Since photons and neutrons cause different biological effects, the dosage terms above are multiplied by the relative biological effects of different tissues to obtain the equivalent dose.

[0121] The neutron capture therapy system including a biodosimeter is further described below with reference to the accompanying drawings: Figure 5 The neutron source in the neutron capture therapy system shown is an accelerator neutron source. The charged particles generated by the accelerator 10 form a charged particle beam P. The charged particle beam strikes the target T in the neutron generating device 20, forming a mixed radiation field containing thermal neutrons, fast neutrons, and ultrathermal neutrons. The mixed radiation field passes through the beam shaper 30 in sequence, where the reflector 31 reflects the neutrons that are spreading outward back to the mixed radiation field, the decelerator 32 decelerates them, and the thermal neutron absorber 33 absorbs the lower-energy thermal neutrons, forming a neutron beam N dominated by ultrathermal neutrons. The neutron beam is focused by the collimator 40 to accurately irradiate the part of the patient to be irradiated. In addition, in order to prevent the radiation rays in the beam shaper 30 from spreading out, a radiation shield 34 is set at the rear of the beam shaper 30, close to the beam exit.

[0122] To prevent radiation from damaging other normal tissues during treatment, it is often necessary to position the patient in the irradiation room before neutron beam irradiation, such as... Figure 5 As shown, before neutron irradiation, the patient's irradiation site is pre-positioned to the intersection of the X and Y axes of the neutron beam direction according to the direction of the neutron beam passing through the collimator to achieve precise irradiation.

[0123] To assess the neutron radiation dose of the neutron beam at the patient's treatment site in the irradiation room, a biodosimeter A needs to be installed at the predetermined location in the irradiation room. The biodosimeter is used to measure the radiation dose at the intersection of the X and Y axes in the direction of the neutron beam. The radiation field where the biodosimeter is located is a mixed neutron and gamma radiation field. The dose calculated by the biodosimeter based on the degree of protein degradation at the intersection point and inputting it into the standard curve is the relative radiation dose of the protein in the radiation field used to create the standard curve. The neutron dose and gamma dose in the mixed radiation field need to be calculated separately according to the method in <Example 2>.

[0124] In addition to being located in Figure 5 In addition to the location shown, the biodosimeter can also be placed at other locations in the irradiation chamber to measure the radiation dose at the location of the biodosimeter. Since the biodosimeter is simple and lightweight to use, it can be placed at any location in the irradiation chamber to evaluate the radiation dose at that location, and further determine and control radiation pollution in the irradiation chamber. It can be seen that the biodosimeter is of great significance in the neutron capture system.

[0125] The biological dosimeter and neutron capture therapy system disclosed in this invention are not limited to the contents described in the above embodiments and the structures shown in the accompanying drawings. Any obvious changes, substitutions, or modifications made based on this invention are within the scope of protection claimed by this invention.

Claims

1. A biological dosimeter, characterized in that, The biodosimeter measures the radiation dose received by the protein based on the degree of protein degradation in the radiation field. The biodosimeter selects proteins with different sensitivities to radiation according to different radiation doses, and quantifies the degree of protein degradation by the ratio of the molecular weight of the protein after radiation irradiation to the molecular weight of the protein before radiation irradiation. The ratio of the molecular weight of the protein after radiation irradiation to the molecular weight of the protein before radiation irradiation has a linear relationship with the radiation dose received by the protein.

2. The biological dosimeter as described in claim 1, characterized in that, The radiation includes gamma radiation, proton radiation, heavy ion radiation, or a mixture of neutron and gamma radiation.

3. The biological dosimeter according to any one of claims 1 to 2, characterized in that, When the radiation dose received by the protein is higher than 1000 Gy, the biodosimeter selects casein as the protein to measure the radiation dose received.

4. The biological dosimeter according to any one of claims 1 to 2, characterized in that, The concentration of the protein is 0.2 g / L to 0.6 g / L, and the radiation dose measured by the protein is 100 Gy to 500 Gy.

5. The method of using the biological dosimeter as described in any one of claims 1 to 4, characterized in that, The biodosimeter measures radiation dose through the following steps: The steps for plotting a standard curve are as follows: prepare multiple groups of protein solutions, place the protein solutions in a radiation field and expose them to different doses of radiation, terminate the radiation, measure the radiation dose received by each group of protein solutions and analyze the degree of protein degradation after irradiation, and plot and fit a standard curve of radiation dose and degree of protein degradation. The steps for measuring the radiation dose to be measured are as follows: Prepare a protein solution of the same concentration as in the above steps, place the protein solution in the radiation environment to be measured to receive radiation, terminate the radiation and measure the degree of protein degradation after radiation, and substitute the value that can reflect the degree of protein degradation into the standard curve to calculate the radiation dose received by the protein during the time of radiation exposure.

6. The method of using the biological dosimeter as described in claim 5, characterized in that, When the radiation dose calculated by measuring the radiation dose to be measured is not within the range of radiation doses used when plotting the standard curve, the accuracy of measuring the radiation dose to be measured can be improved by adjusting the time when the protein solution is exposed to radiation in the step of measuring the radiation dose to be measured so that the radiation dose received by the protein solution is within the range of radiation doses used when plotting the standard curve.

7. The method of using the biological dosimeter as described in any one of claims 5 to 6, characterized in that, The protein solution is a bovine serum albumin solution with a concentration of 0.2 g / L to 0.6 g / L.

8. The method of using the biological dosimeter as described in any one of claims 1 to 4, characterized in that, When the radiation is a mixture of neutron and gamma radiation, the method further includes: plotting a standard curve using the degree of protein degradation in gamma radiation, and calculating the radiation intensity corresponding to the degree of protein degradation Xi as the relative radiation intensity of the protein in gamma radiation Di = Mj + Nj, where Mj is the gamma intensity, Nj is the equivalent intensity of neutrons relative to gamma, and the actual neutron intensity received by the protein is the ratio of the equivalent intensity of neutrons relative to gamma to the conversion coefficient Ki at the protein degradation concentration, wherein the conversion coefficient Ki is the ratio of gamma intensity to neutron intensity at a specific degree of protein degradation.

9. A neutron capture therapy system, characterized in that, The neutron capture therapy system includes a neutron source, a beam shaper, a collimator, and a biodosimeter as described in any one of claims 1 to 4, wherein the neutron source is used to generate a neutron beam, the beam shaper is located behind the neutron source and adjusts fast neutrons in the neutron beam with a broad energy spectrum generated by the neutron source into hyperthermal neutrons, the collimator is located behind the beam shaper to focus the hyperthermal neutrons, and the biodosimeter is used to measure the radiation dose at the location of the biodosimeter behind the collimator.

10. The neutron capture therapy system as described in claim 9, characterized in that, The beam shaper includes a reflector and a retarder, wherein the reflector surrounds the retarder and is used to reflect neutrons diffusing out of the beam shaper back into the retarder, and the retarder is used to slow fast neutrons into hyperthermal neutrons.

Citation Information

Patent Citations

  • Method of measuring exposure dosage of ionizing radiation

    CN101184998A

  • Radiant ray detection system and radiant ray detection method for neutron capture treatment system

    CN106552321A